Lapatinib in metastatic breast cancer

By Frenel J-S   Bourbouloux E   Berton-Rigaud D   Sadot-Lebouvier S   Zanetti A   Campone M  

Women's Health, Vol. 5, Iss. 6, 2009-11 ,pp. : 603-612

Future Medicine

Access to resources Recommend Favorite

Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer

By Kaufman B.   Wu Y.   Amonkar M.M.   Sherrill B.   Bachelot T.   Salazar V.   Viens P.   Johnston S.  

Current Medical Research and Opinion, Vol. 26, Iss. 5, 2010-05 ,pp. : 1065-1073

Informa Healthcare

Access to resources Recommend Favorite

Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel

By Steger Guenther G.  

Wiener klinische Wochenschrift, Vol. 122, Iss. 11-12, 2010-06 ,pp. : 368-379

Springer Publishing Company

Access to resources Recommend Favorite

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-08 ,pp. : 555-559

Karger

Access to resources Recommend Favorite

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 129-135

Karger

Access to resources Recommend Favorite